Kairaba Pharmaceuticals Limited Pharmaceutical Import Profile — Gambia (DGFT 2022–2026)

Name: Kairaba Pharmaceuticals Limited Pharmaceutical Import Records from India — 2 Products, $650.7K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kairaba Pharmaceuticals Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $650.7K Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Kairaba Pharmaceuticals Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Medinomics Health Care Private Limited	$304.1K	33	24.7%
Socomed Pharma Private Limited	$302.8K	35	24.6%
Syncom Formulations India Limited	$302.2K	64	24.5%
Syncom Formulations (india) Limited	$243.7K	49	19.8%
Sangharsh Lifecare Private Limited	$53.9K	9	4.4%
Kwality Pharmaceuticals Limited	$25.1K	3	2.0%

Kairaba Pharmaceuticals Limited sources from 6 verified Indian suppliers across 128 distinct formulations. The supply base is diversified across 6 suppliers, reducing single-source dependency risk.

What Formulations Does Kairaba Pharmaceuticals Limited Import?

Formulation	Value	Ships
Super peptee tablets cyproheptadine TAB	$57.0K	2
Dyclosa 50 tablets new artwork eachenteric coated tablet cont. diclofenac sodium BP 50	$50.0K	1
Dyclosa 50 tablets (new with hologram (multicolor shipper Each enteric coated tablet contains diclofenac	$47.6K	1
Aniclox CAPS 500MG. ampicillin and cloxacillin capsules 1498000 CAPS @ usd 0.02949 x 100 x 10 x 10 t 01 x 60 x	$44.2K	1
Cortim tablets (white round tablet (eachuncoated tablet cont.trimethoprim BP 80MG,sulfamethoxazole BP 400	$34.8K	1
Killpane tablets acetylsalicylic acid	$32.5K	1

What Products Does Kairaba Pharmaceuticals Limited Import?

Top Products by Import Value

1Acetylsalicylic$355.7K 2Salicylic$295.0K

Kairaba Pharmaceuticals Limited Therapeutic Categories — 1 Specializations

Kairaba Pharmaceuticals Limited imports across 1 therapeutic categories, with Combination Drugs (100.0%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Combination Drugs

2 products · 100.0% · $650.7K

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Acetylsalicylic	Combination Drugs	$355.7K	8	6.6%	4
2	Salicylic	Combination Drugs	$295.0K	7	1.8%	9

Key Metrics

Total Import Value$650.7K

Products2

Shipments15

Categories1

CountryGambia

#1 Rankings0

Indian Suppliers6

Formulations128

Top Categories

Combination Drugs100.0%

Indian Suppliers

Last updated: March 28, 2026

Kairaba Pharmaceuticals Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Kairaba Pharmaceuticals Limited is a prominent pharmaceutical importer and distributor based in Banjul, The Gambia. Established in 1991, the company has been a key player in the Gambia pharmaceutical sector, focusing on the importation and distribution of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Operating under the license number MCA/IMP/0002/2025, Kairaba Pharmaceuticals Limited is headquartered at 61 Kairaba Avenue, K.S.M.D., The Gambia. (mca.gm)

The company plays a pivotal role in the Gambia pharmaceutical distribution network, serving as a primary wholesaler and distributor. By sourcing a diverse range of pharmaceutical products, Kairaba Pharmaceuticals Limited ensures the availability of essential medications across the country, thereby contributing significantly to the healthcare infrastructure of The Gambia.

2Distribution Network

Kairaba Pharmaceuticals Limited operates a centralized distribution model from its headquarters in Banjul. While specific details about warehouse locations and logistics capabilities are not publicly disclosed, the company's extensive import activities suggest a well-established distribution network capable of serving the entire Gambian market. The company's strategic location in Banjul facilitates efficient access to both domestic and international markets, enhancing its logistical operations.

Supplier Relationship Intelligence — Kairaba Pharmaceuticals Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Kairaba Pharmaceuticals Limited's sourcing strategy exhibits a high degree of concentration, with a significant portion of its imports originating from a select group of Indian suppliers. The company's total import value from India stands at $651,000 USD, distributed across 15 shipments. The top five products imported include Acetylsalicylic acid ($356,000 USD), Salicylic acid ($295,000 USD), and other combination drugs, collectively accounting for 100% of the company's imports.

This concentrated sourcing approach may present risks related to supply chain disruptions, currency fluctuations, and dependency on a limited number of suppliers. However, it also indicates a strategic choice to maintain consistent product quality and pricing. The stability of these supplier relationships is crucial for Kairaba Pharmaceuticals Limited's operational continuity.

2Supply Chain Resilience

The resilience of Kairaba Pharmaceuticals Limited's supply chain is closely tied to its reliance on a limited number of Indian suppliers. The company's import data reveals a total of 15 shipments from six unique suppliers, with the top five suppliers accounting for the majority of the import value. This suggests a potential vulnerability to supply chain disruptions, such as production delays or geopolitical issues affecting India.

To enhance supply chain resilience, Kairaba Pharmaceuticals Limited could consider diversifying its supplier base and establishing relationships with additional manufacturers. This strategy would mitigate risks associated with over-reliance on a few suppliers and ensure a more robust supply chain capable of adapting to unforeseen challenges.

3Strategic Implications

Kairaba Pharmaceuticals Limited's concentrated sourcing pattern positions it as a significant player in the Gambia pharmaceutical market, particularly in the importation of combination drugs. This focus allows the company to leverage economies of scale, negotiate favorable terms with suppliers, and maintain a competitive edge in pricing.

For Indian exporters, this presents an opportunity to strengthen existing partnerships and explore avenues for expanding their product offerings to Kairaba Pharmaceuticals Limited. By aligning with the company's strategic focus on combination drugs, Indian suppliers can enhance their market presence in The Gambia and contribute to the diversification of Kairaba Pharmaceuticals Limited's product portfolio.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Gambia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Gambia

1Regulatory Authority & Framework

The Medicines Control Agency (MCA) is the primary regulatory body overseeing the importation and distribution of pharmaceutical products in The Gambia. Established under the Medicines and Related Products Act, 2014, the MCA is responsible for ensuring the safety, efficacy, and quality of medicines available in the country. (mca.gm)

Key legislation governing pharmaceutical imports includes the Medicines and Related Products Act, 2014, which outlines the requirements for the registration and importation of medicines. The MCA enforces strict guidelines to prevent the entry of substandard or counterfeit medicines into the Gambian market. These regulations are designed to protect public health and maintain the integrity of the pharmaceutical supply chain.

2Import Licensing & GMP

Importers in The Gambia must obtain an import permit from the MCA before bringing pharmaceutical products into the country. This process involves submitting an application that includes detailed information about the products, their manufacturers, and intended use. The MCA charges a non-refundable processing fee for import permit applications. (mca.gm)

The MCA recognizes Good Manufacturing Practice (GMP) certifications from reputable authorities, including the European Union (EU), World Health Organization (WHO), and Pharmaceutical Inspection Co-operation Scheme (PIC/S). Importers are required to ensure that their suppliers hold valid GMP certifications from these recognized bodies to guarantee the quality and safety of imported medicines.

3Quality & Labeling

Imported pharmaceutical products must undergo batch testing and meet stability requirements as stipulated by the MCA. This ensures that medicines are safe, effective, and suitable for the Gambian market. Additionally, labeling must be in English and include the manufacturer's name and address, as well as a registration number assigned by the MCA. Importers are also required to provide samples for testing before importation to verify compliance with these standards. (op.gov.gm)

4Recent Regulatory Changes

Between 2024 and 2026, the MCA has implemented stricter guidelines for the importation of medicines into The Gambia. These regulations include requirements for English labeling, inclusion of the manufacturer's name and address, and the display of registration numbers on medical packages. Importers must also provide samples for testing before importation to ensure compliance with these standards. (op.gov.gm)

TransData Nexus Research · Gambia regulatory databasesMar 2026

Seller's Guide — How to Become a Supplier to Kairaba Pharmaceuticals Limited

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Kairaba Pharmaceuticals Limited, particularly in the supply of combination drugs and other essential medications. The company's concentrated sourcing pattern suggests potential gaps in its current supplier base, which could be addressed by establishing partnerships with additional Indian manufacturers. By offering high-quality products that meet the MCA's regulatory standards, new suppliers can position themselves as valuable partners to Kairaba Pharmaceuticals Limited and expand their presence in the Gambian market.

2Requirements & Qualifications

Indian exporters seeking to supply Kairaba Pharmaceuticals Limited and the Gambian market must ensure that their products comply with the MCA's regulatory requirements. This includes obtaining GMP certifications from recognized authorities such as the EU, WHO, or PIC/S. Additionally, products must meet labeling standards, including English language requirements and inclusion of the manufacturer's name and address. Importers are also required to provide samples for testing before importation to verify compliance with these standards. (op.gov.gm)

3How to Approach

To establish a partnership with Kairaba Pharmaceuticals Limited, Indian exporters should initiate contact by providing detailed product information, including specifications, certifications, and compliance with MCA regulations. Participating in tenders and responding to requests for proposals can also be effective strategies. Understanding the regulatory filing process and ensuring timely submission of necessary documentation will facilitate smoother entry into the Gambian market. Building a relationship with Kairaba Pharmaceuticals Limited requires a commitment to quality, reliability, and adherence to local regulations, with an emphasis on long-term collaboration.

TransData Nexus Research · Industry procurement practicesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Kairaba Pharmaceuticals Limited identified across shipments using consignee name normalization, aggregating 2 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Kairaba Pharmaceuticals Limited's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 15 individual customs records matching Kairaba Pharmaceuticals Limited.
5.Supplier Verification: Kairaba Pharmaceuticals Limited sources from 6 verified Indian suppliers across 128 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

1 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Kairaba Pharmaceuticals Limited

Kairaba Pharmaceuticals Limited — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Kairaba Pharmaceuticals Limited?

What Formulations Does Kairaba Pharmaceuticals Limited Import?

What Products Does Kairaba Pharmaceuticals Limited Import?

Top Products by Import Value

Kairaba Pharmaceuticals Limited Therapeutic Categories — 1 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Indian Suppliers

Kairaba Pharmaceuticals Limited — Corporate Profile & Information

1Company Overview

2Distribution Network

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Kairaba Pharmaceuticals Limited

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Gambia — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Kairaba Pharmaceuticals Limited — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Kairaba Pharmaceuticals Limited

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Kairaba Pharmaceuticals Limited

What products does Kairaba Pharmaceuticals Limited import from India?

Who supplies pharmaceuticals to Kairaba Pharmaceuticals Limited from India?

What is Kairaba Pharmaceuticals Limited's total pharmaceutical import value?

What therapeutic categories does Kairaba Pharmaceuticals Limited focus on?

Get Full Kairaba Pharmaceuticals Limited Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology